Breaking News, Collaborations & Alliances

Biocartis and Amgen Sign CDx Agreement

For the treatment of certain solid tumors

Biocartis Group NV has signed a new companion diagnostic (CDx) development agreement with Amgen, aimed at the development of Idylla(TM) CDx biomarker tests for a novel oncology compound to be used in the treatment of certain solid tumors.    This is the second CDx agreement that Biocartis has signed with Amgen. The first CDx agreement between both companies was announced on December 4, 2017 and aims to register the Idylla(TM) KRAS Mutation Test and the Idylla(TM) NRAS-BRAF Mutation Test ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters